Senseonics Announces FDA Approval for a Non-Adjunctive Indication (Dosing Claim) for the Eversense® 90-day CGM System
With a non-adjunctive claim, Eversense users will soon be able to manage their diabetes dosing decisions without confirming with fingersticks...